Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice

Fan, Qiuling; Liao, Jie; Kobayashi, Michimasa; Yamashita, M; Gu, Leyi; Gohda, Tomohito; Suzuki, Yusuke; Wang, Li Ning; Horikoshi, Satoshi; Tomino, Yasuhiko

doi:10.1093/ndt/gfh499

Cited by 91 publications

(73 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…13 However, to our knowledge, this is the first report that ARBs inhibit TNF␣-induced RAGE expression in human endothelial cells, supporting that ARBs have antiatherogenic effects. TNF␣-induced endothelial RAGE expression is regulated by the activation of the NF-B site in the RAGE promoter.…”

Section: Arbs Reduce the Tnf␣-induced Rage Protein And Mrna Expressionmentioning

confidence: 58%

Blockade of Angiotensin II Receptors Reduces the Expression of Receptors for Advanced Glycation End Products in Human Endothelial Cells

Fujita

Okuda

Tsukamoto

et al. 2006

ATVB

View full text Add to dashboard Cite

Objectives-Receptors for advanced glycation end products (RAGEs) play crucial roles in atherogenesis. Because tumor necrosis factor ␣ (TNF␣) is expressed and upregulates RAGE expression in atherosclerotic lesions, the TNF␣-RAGE interaction might be involved in the inflammatory process of atherogenesis. On the other hand, an angiotensin II type-1 receptor blocker (ARB), widely used as an antihypertensive drug, has been reported to have also antiatherosclerotic effects. Thus we investigated whether an ARB exerts antiatherosclerotic effects via inhibiting the TNF␣-RAGE interaction. On the other hand, an angiotensin II type-1 receptor blocker (ARB), widely used as an antihypertensive drug, has been reported to have also antiatherosclerotic such as attenuating neointimal formation, decreasing vascular smooth muscle cell (VSMC) proliferation and diminishing vascular inflammation. 8 Considering these results, we hypothesized that an ARB has antiatherosclerotic effects via inhibiting TNF␣-RAGE interaction, thus leading to the decrease in the inflammatory process of atherosclerosis. We tested this hypothesis using human endothelial cells.

show abstract

Section: Arbs Reduce the Tnf␣-induced Rage Protein And Mrna Expressionmentioning

confidence: 58%

Blockade of Angiotensin II Receptors Reduces the Expression of Receptors for Advanced Glycation End Products in Human Endothelial Cells

Fujita

Okuda

Tsukamoto

et al. 2006

ATVB

View full text Add to dashboard Cite

show abstract

“…It has been reported that the ARBs olmesartan [9][10][11] and candesartan 12) inhibited the formation and accumulation of AGEs in vitro 9) and in diabetic animal models. [10][11][12] However, whether they can do so clinically is not clear.…”

Section: Discussionmentioning

confidence: 99%

“…6,7) Also, an association between AGEs and diabetic microangiopathy has been reported, and intervention to reduce AGEs is considered an important strategy in treating diabetic nephropathy. 8) Miyata, et al reported that ARBs or angiotensin-converting enzyme inhibitors (ACE-Is) decreased AGE formation in vitro via radical scavenging and transition metal chelation, 9) and it has been shown that some ARBs reduced renal AGE accumulation and proteinuria in diabetic rodents in vivo [10][11][12] to a degree similar to that of an ACE-I. 13) Sebekova, et al reported that treatment with the ACE-I ramipril for 2 months significantly decreased the fluorescent AGE level in 12 subjects with nondiabetic nephropathy.…”

mentioning

confidence: 99%

Effects of 12-Month Valsartan Therapy on Glycation and Oxidative Stress Markers in Type 2 Diabetic Subjects With Hypertension

et al. 2008

View full text Add to dashboard Cite

SUMMARYAlthough it has been reported that angiotensin II receptor blockers inhibited the formation and accumulation of advanced glycation endproducts (AGEs) in vitro and in vivo, whether they can do so clinically is not clear. We investigated the effects of 12-month valsartan therapy on various markers of inflammation, glycation, and oxidation in type 2 diabetic subjects with hypertension.We started 40 mg/day valsartan treatment in 15 type 2 diabetic patients with hypertension. In 6 patients, the dose of valsartan was increased to 80 mg/day after 6 months and maintained until 12 months. Metabolic parameters including BMI and serum high molecular weight (HMW)-adiponectin, high-sensitivity C-reactive protein (hs-CRP) as an inflammation marker, AGEs, paraoxonase activity, platelet-activating factor (PAF)-acetylhydrolase activity, and urine 8-isoprostane levels were measured at baseline and after 6 and 12 months of treatment. Urine microalbumin level and carotid artery intimamedia thickness (IMT) were also measured.Even after valsartan therapy, the blood pressure levels of the patients were not decreased significantly. Serum AGEs and urine 8-isoprostane levels decreased at both 6 and 12 months (P < 0.05 for both), although other metabolic and oxidative markers were unchanged. Though urine microalbumin levels tended to be decreased after 6 and 12 months of valsartan treatment, the changes were not significant. Mean IMT at 12 months was not changed from the baseline value. In conclusion, the findings suggest that treatment with valsartan, even at a low dose, may ameliorate some glycation and oxidative stress markers independently of an effect on blood pressure in hypertensive type 2 diabetic subjects. (Int Heart J 2008; 49: 681-689)

show abstract

“…The resulting c-DNA was amplified with a Takara PCR Thermal Cycler (Takara Shuzo Co., Ltd., Kyoto, Japan). The sequences of RAGE primers were as follows: GAPDH, sense 5'-AGC CGC ATC TTC TTG TGC A-3', and antisense 5'-GCC GTG AGT GGA GTC ATA CT-3'; and RAGE, sense 5'-CAG GGT CAC AGA AAC CGG-3', and antisense 5'-ATT CAG CTC TGC ACG TTC CT -3' [4]. mRNA of TGF-b was analyzed with mouse transforming growth factor-beta (TGF-b) and that of GAPDH with a Genes Dual-PCR Kit (Maxim Biotech Inc., MD, USA).…”

Section: Semi-quantitative Rt-pcr For Detection Of Receptor For Advanmentioning

confidence: 99%

Pioglitazone Improves Obesity Type Diabetic Nephropathy: Relation to the Mitigation of Renal Oxidative Reaction

Hirasawa

Matsui²,

Yamane³

et al. 2008

Exp. Anim.

View full text Add to dashboard Cite

show abstract

Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice

Abstract: These findings suggest that candesartan, an ARB, reduces AGE accumulation and subsequent albuminuria by down-regulating the NADPH oxidase p47phox component and iNOS expression and by attenuating RAGE expression in type 2 diabetic KK/Ta mouse kidneys.

Cited by 91 publications

References 15 publications

Blockade of Angiotensin II Receptors Reduces the Expression of Receptors for Advanced Glycation End Products in Human Endothelial Cells

Blockade of Angiotensin II Receptors Reduces the Expression of Receptors for Advanced Glycation End Products in Human Endothelial Cells

Effects of 12-Month Valsartan Therapy on Glycation and Oxidative Stress Markers in Type 2 Diabetic Subjects With Hypertension

Pioglitazone Improves Obesity Type Diabetic Nephropathy: Relation to the Mitigation of Renal Oxidative Reaction

Contact Info

Product

Resources

About